Therapeutically active compounds and their methods of use
Provided are crystalline forms of 2-Methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol mesylate useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof said compound.
1. An isolated crystalline form of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol mesylate, characterized by an X-ray powder diffraction pattern substantially similar to FIG. 40 or FIG. 43 .
2. A method of treating an advanced hematologic malignancy selected from acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to a subject in need thereof a therapeutically effective dose of a crystalline form of claim 1 .
3. A method of treating an advanced hematologic malignancy selected from acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to subject in need thereof a pharmaceutical composition comprising a therapeutically effective dose of a crystalline form of claim 1 and one or more pharmaceutically acceptable carrier(s).
4. A method of treating an advanced hematologic malignancy selected from acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, and lymphoma, each characterized by the presence of a mutant allele of IDH2, comprising administering to a subject in need thereof a crystalline form of claim 1 at a dose of from about 30 mg to about 300 mg free-base equivalent strength, once daily or twice daily.
5. The method of claim 4 , wherein the dose is about 75 mg, once daily or twice daily.
6. The method of claim 4 , wherein the dose is about 100 mg, once daily or twice daily.
7. The method of claim 4 , wherein the dose is about 150 mg, once daily or twice daily.
8. The method of claim 4 , wherein the dose is about 200 mg, once daily or twice daily.
9. The method of claim 4 , wherein the dosage is an oral dosage form.
10. The method of claim 9 , wherein the oral dosage form is a tablet.
11. The method of claim 4 , wherein the dose is administered once daily.
12. The method of claim 4 , wherein the dose is administered twice daily.
13. The method of claim 4 , wherein the dose is administered orally as any combination of 5, 10, 50, or 200 mg free-base equivalent strength tablets, twice daily or once daily.
14. The method of claim 4 , wherein the advanced hematologic malignancy is selected from acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and lymphoma.
15. The method of claim 14 , wherein the advanced hematologic malignancy is acute myelogenous leukemia (AML).
16. The method of claim 14 , wherein the advanced hematologic malignancy is myelodysplastic syndrome (MDS).
17. The method of claim 14 , wherein the advanced hematologic malignancy is chronic myelomonocytic leukemia (CMML).
18. The method of claim 14 , wherein the advanced hematologic malignancy is lymphoma.
19. The method of claim 6 , wherein the dose is about 100 mg, once daily.
20. The method of claim 15 , wherein the dose is about 100 mg, once daily.